Search
ICON PLC
ICLRAdd to Watchlist
162.440USD
+4.270+2.70%
Market hours （ET）Quotes delayed by 15 min
12.44BMarket Cap
21.76P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of ICON PLC is 7.18, ranking 306 out of 388 in the Biotechnology & Medical Research industry. The average price target is 213.50, with a high of 235.00 and a low of 172.00.
Analyst Rating
Based on
18
analysts
Buy
Current Rating
160.133
Target Price
+9.68%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
ICON PLC
ICLR
18
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is ICON PLC's expected revenue for the next quarter?
ICON PLC's expected revenue is 2.01B.
What is ICON PLC's price target?
Analysts forecast that ICON PLC's price target is USD 213.50, with the highest forecast at USD 235.00 and the lowest forecast at USD 172.00.
How have ICON PLCICLR's recent earnings per share performed?
The market expectation was USD 1.37, while ICON PLCICLR's earnings per share (EPS) for the previous quarter was USD -1.44. EPS for the next quarter is expected at USD 2.54.
What is the analyst rating for ICON PLC?
Based on the ratings of ICON PLC's stock from 18 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
